TR201903603T4 - Hareket bozukluklarının tedavisinde kullanım için A2A reseptörü antagonistleri. - Google Patents

Hareket bozukluklarının tedavisinde kullanım için A2A reseptörü antagonistleri. Download PDF

Info

Publication number
TR201903603T4
TR201903603T4 TR2019/03603T TR201903603T TR201903603T4 TR 201903603 T4 TR201903603 T4 TR 201903603T4 TR 2019/03603 T TR2019/03603 T TR 2019/03603T TR 201903603 T TR201903603 T TR 201903603T TR 201903603 T4 TR201903603 T4 TR 201903603T4
Authority
TR
Turkey
Prior art keywords
dopa
methods
treatment
receptor antagonists
adenosine
Prior art date
Application number
TR2019/03603T
Other languages
English (en)
Inventor
Kase Hiroshi
Mori Akihisa
Waki Yutaka
Ohsawa Yutaka
Karasawa Akira
Kuwana Yoshihisa
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27663091&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201903603(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of TR201903603T4 publication Critical patent/TR201903603T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Buluş hareket bozukluklarını, bir veya daha fazla adenozin A2A reseptörü antagonistinin etkili miktarıyla tedavi etmenin usullerine; L-DOPA alan hastalarda L-DOPA'nın olumsuz etkilerini azaltma usullerine; L-DOPA'nın bir veya daha fazla A2A reseptörü antagonistinin etkili miktarıyla kombinasyonuyla, Parkinson hastalarının L-DOPA'nın subklinik dozlarıyla tedavisi için usullere/bileşimlere; etkili tedavi için en az bir adenozin A2A reseptörü antagonisti, L-DOPA ve bir dopamin agonisti ve/veya COMT inhibitörü ve/veya MAO inhibitörünün birlikte uygulandığı usullere; önceden/sonradan L-DOPA uygulamadan tek başına veya bir dopamin agonisti ve/veya COMT inhibitörü ve/veya MAO inhibitörüyle birlikte bir adenozin A2A reseptörü antagonisti uygulayarak Parkinson hastalığının etkili tedavisini uzatmak, L-DOPA motor komplikasyonunu geciktirmek veya önlemek için usullere ilişkindir.
TR2019/03603T 2002-01-28 2003-01-28 Hareket bozukluklarının tedavisinde kullanım için A2A reseptörü antagonistleri. TR201903603T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35241302P 2002-01-28 2002-01-28

Publications (1)

Publication Number Publication Date
TR201903603T4 true TR201903603T4 (tr) 2019-04-22

Family

ID=27663091

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/03603T TR201903603T4 (tr) 2002-01-28 2003-01-28 Hareket bozukluklarının tedavisinde kullanım için A2A reseptörü antagonistleri.

Country Status (16)

Country Link
US (7) US20040198753A1 (tr)
EP (4) EP2260850B1 (tr)
JP (3) JP4376630B2 (tr)
KR (5) KR20100056569A (tr)
CN (3) CN1646132A (tr)
AU (2) AU2003207734C1 (tr)
BR (1) BR0306919A (tr)
CA (2) CA2473864C (tr)
CO (1) CO5601022A2 (tr)
EA (1) EA200400982A1 (tr)
ES (2) ES2686123T3 (tr)
HU (2) HUE043353T2 (tr)
MX (1) MXPA04007299A (tr)
PT (2) PT2260850T (tr)
TR (1) TR201903603T4 (tr)
WO (1) WO2003063876A2 (tr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
EA200400982A1 (ru) * 2002-01-28 2004-12-30 Киова Хакко Когио Ко., Лтд. Способы лечения пациентов, страдающих от нарушения движений
EA008339B1 (ru) † 2002-08-30 2007-04-27 Киова Хакко Когио Ко., Лтд. Способы лечения пациентов, страдающих синдромом усталых ног или связанными с ним заболеваниями
US7414058B2 (en) * 2002-12-19 2008-08-19 Schering Corporation Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
US20060106040A1 (en) * 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
AR056615A1 (es) * 2002-12-27 2007-10-17 Kyowa Hakko Kogyo Kk Un metodo de tratamiento de trastornos de la conducta
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
US7998970B2 (en) * 2004-12-03 2011-08-16 Proteosys Ag Use of finasteride, dutasteride and related compounds for the prevention or treatment of neurologically-associated disorders
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
US7851478B2 (en) 2005-06-07 2010-12-14 Kyowa Hakko Kirin Co., Ltd. Agent for preventing and/or treating movement disorder
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
US8802002B2 (en) 2006-12-28 2014-08-12 3M Innovative Properties Company Dimensionally stable bonded nonwoven fibrous webs
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
US20090118376A1 (en) * 2007-11-02 2009-05-07 Ru-Band Lu Memantine Protects Inflammation-Related Degeneration of Dopamine Neurons Through Inhibition of Over-Activated Microglia and Release of Neurotrophic Factors from Astroglia
CA2727555C (en) * 2008-06-12 2016-10-04 Global Kinetics Corporation Pty Ltd Detection of hypokinetic and/or hyperkinetic states
MX2011007678A (es) * 2009-01-20 2011-08-08 Schering Corp Metodos para aliviar o tratar señales y/o sintomas asociados con enfermedad de parkinson de moderada a severa.
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
AU2013271841B2 (en) * 2012-06-05 2018-03-08 International Stem Cell Corporation Method of prevention of neurological diseases
US9012640B2 (en) * 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
EP2961319A4 (en) 2013-03-01 2016-10-19 Global Kinetics Corp Pty Ltd SYSTEM AND METHOD FOR EVALUATING PULSE CONTROL DISORDER
US10040817B2 (en) 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
JP6381883B2 (ja) * 2013-10-04 2018-08-29 国立大学法人千葉大学 不随意運動の予防及び／又は治療組成物
WO2015131244A1 (en) 2014-03-03 2015-09-11 Global Kinetics Corporation Pty Ltd Method and system for assessing motion symptoms
WO2016148260A1 (ja) * 2015-03-17 2016-09-22 協和発酵キリン株式会社 医薬組成物
CA2988918A1 (en) 2015-06-19 2016-12-22 Biotie Therapies, Inc. Controlled-release tozadenant formulations
CN109414417A (zh) * 2016-03-17 2019-03-01 约翰·霍普金斯大学 通过paris的法尼基化预防或治疗帕金森症的方法
EP3436013A4 (en) 2016-03-31 2019-11-13 Versi Group, LLC COMPOSITIONS BASED ON OPIACE RECEPTOR DELTA / OPAACEOUS RECEPTOR DELTA OPTIONAL AGONIST, AND METHODS FOR TREATING PARKINSON'S DISEASE
WO2018013951A1 (en) * 2016-07-15 2018-01-18 Northwestern University Targeting adenosine a2a receptors for the treatment of levodopa-induced dyskinesias
US20220168311A1 (en) 2019-03-21 2022-06-02 Kyowa Kirin Co., Ltd. Therapeutic agent for parkinson's disease
EP3714888A1 (en) * 2019-03-25 2020-09-30 Assistance Publique - Hôpitaux De Paris Compounds for use in the treatment of adcy5-related dyskinesia
JP7382737B2 (ja) * 2019-05-13 2023-11-17 東和薬品株式会社 イストラデフィリン製剤
WO2022167778A1 (en) 2021-02-02 2022-08-11 Haiku Therapeutics Ltd Ebselen as adenosine receptor modulator

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006976A1 (fr) 1990-10-18 1992-04-30 Kyowa Hakko Kogyo Co., Ltd. Derive de xanthine
US5484920A (en) 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
JP2928386B2 (ja) 1992-07-08 1999-08-03 協和醗酵工業株式会社 うつ病治療剤
ATE208199T1 (de) 1993-07-27 2001-11-15 Kyowa Hakko Kogyo Kk Arzneimittel gegen parkinsonsche krankheit
AU1823895A (en) 1994-02-23 1995-09-11 Kyowa Hakko Kogyo Co. Ltd. Xanthine derivative
JP4195729B2 (ja) 1997-03-24 2008-12-10 協和醗酵工業株式会社 ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
ATE325610T1 (de) * 1997-09-05 2006-06-15 Kyowa Hakko Kogyo Kk Xanthinderivative zur behandlung von hirnischämie
EP0975345A1 (en) * 1997-11-26 2000-02-02 Cerebrus Pharmaceuticals Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
EP1054012B1 (en) 1998-01-05 2003-06-11 Eisai Co., Ltd. Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
WO1999043678A1 (fr) 1998-02-24 1999-09-02 Kyowa Hakko Kogyo Co., Ltd. Medicaments et prophylaxie contre la maladie de parkinson
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
GB9819384D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
AU756144B2 (en) 1998-09-22 2003-01-02 Kyowa Hakko Kogyo Co. Ltd. (1,2,4)triazolo(1,5-c)pyrimidine derivatives
EP1177797A1 (en) 1999-05-12 2002-02-06 Fujisawa Pharmaceutical Co., Ltd. Novel use
GB9915437D0 (en) * 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
PT1221444E (pt) 1999-07-02 2005-11-30 Eisai Co Ltd Derivados de imidazole condensados e medicamentos para a diabetes mellitus
FR2796759B1 (fr) 1999-07-23 2001-11-02 Gemplus Card Int Minicarte a circuit integre et procede pour son obtention
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
AUPQ441499A0 (en) 1999-12-02 2000-01-06 Fujisawa Pharmaceutical Co., Ltd. Novel compound
CZ20023199A3 (cs) 2000-02-25 2003-05-14 F. Hoffmann-La Roche Ag Modulátory receptoru adenosinu
EP1510222A3 (en) 2000-04-26 2007-05-23 Eisai R&D Management Co., Ltd. Medicinal compositions promoting bowel movement
KR100520907B1 (ko) 2000-05-26 2005-10-11 쉐링 코포레이션 아데노신 Ａ2ａ수용체 길항제
CA2413086C (en) 2000-06-21 2011-06-28 Alexander Alanine Benzothiazole derivatives
WO2002014282A1 (fr) 2000-08-11 2002-02-21 Eisai Co., Ltd. Composes 2-aminopyridine et leur utilisation comme medicaments
GB0100620D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
EP1379269B1 (en) * 2001-04-09 2009-03-04 Neurosearch A/S Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease
EA200400982A1 (ru) * 2002-01-28 2004-12-30 Киова Хакко Когио Ко., Лтд. Способы лечения пациентов, страдающих от нарушения движений
EA008339B1 (ru) * 2002-08-30 2007-04-27 Киова Хакко Когио Ко., Лтд. Способы лечения пациентов, страдающих синдромом усталых ног или связанными с ним заболеваниями
AU2004244906A1 (en) * 2003-06-10 2004-12-16 Kyowa Hakko Kirin Co., Ltd. A method of treating an anxiety disorder
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
US9238003B2 (en) * 2005-02-04 2016-01-19 Auburn University Extended or continuous wear silicone hydrogel contact lenses for the extended release of comfort molecules

Also Published As

Publication number Publication date
JP4376630B2 (ja) 2009-12-02
EP2044940A3 (en) 2010-11-10
EP2942082A3 (en) 2016-01-27
PT2942082T (pt) 2019-06-06
KR101098209B1 (ko) 2011-12-23
JP2005523898A (ja) 2005-08-11
JP5171556B2 (ja) 2013-03-27
AU2008200611B2 (en) 2011-12-15
ES2686123T3 (es) 2018-10-16
CA2473864C (en) 2013-06-11
US20120122897A1 (en) 2012-05-17
JP5612016B2 (ja) 2014-10-22
JP2012140461A (ja) 2012-07-26
KR101166000B1 (ko) 2012-07-16
MXPA04007299A (es) 2004-10-29
US20040198753A1 (en) 2004-10-07
EP2260850A3 (en) 2013-11-13
EP2260850B1 (en) 2018-07-04
KR20120103740A (ko) 2012-09-19
AU2003207734C1 (en) 2009-10-08
US20170196872A1 (en) 2017-07-13
CN101822676A (zh) 2010-09-08
HUE043353T2 (hu) 2019-08-28
EP2942082B1 (en) 2019-03-06
EP2044940A2 (en) 2009-04-08
WO2003063876A3 (en) 2003-11-27
US20060148827A1 (en) 2006-07-06
KR20150080013A (ko) 2015-07-08
US20180221377A1 (en) 2018-08-09
ES2716404T3 (es) 2019-06-12
BR0306919A (pt) 2004-11-09
JP2009067807A (ja) 2009-04-02
AU2008200611A1 (en) 2008-03-06
KR20100056569A (ko) 2010-05-27
KR20110010829A (ko) 2011-02-07
CN1646132A (zh) 2005-07-27
EP1469855A2 (en) 2004-10-27
US7727993B2 (en) 2010-06-01
CA2813048A1 (en) 2003-08-07
CN101543497A (zh) 2009-09-30
US20140249166A1 (en) 2014-09-04
WO2003063876A2 (en) 2003-08-07
CA2473864A1 (en) 2003-08-07
AU2003207734B2 (en) 2008-02-21
EP2260850A2 (en) 2010-12-15
US7727994B2 (en) 2010-06-01
US20060178379A1 (en) 2006-08-10
PT2260850T (pt) 2018-10-24
EA200400982A1 (ru) 2004-12-30
HUE039348T2 (hu) 2018-12-28
KR20040077763A (ko) 2004-09-06
EP2942082A2 (en) 2015-11-11
CO5601022A2 (es) 2006-01-31

Similar Documents

Publication Publication Date Title
TR201903603T4 (tr) Hareket bozukluklarının tedavisinde kullanım için A2A reseptörü antagonistleri.
UA86621C2 (ru) Антагонисты рецептора глюкагона, их получение и терапевтическое применение
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
SE0203065D0 (sv) Gastric acid secretion inhibiting composition
CY1112478T1 (el) Ενωσεις κιναζολινονης ως αντικαρκινικοι παραγοντες
CR7432A (es) Amidas sustituidas activas del receptor de canabinoide-1
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
DK1587506T3 (da) Administration af capsaicinoider
CY1109860T1 (el) Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις
BRPI0514410A (pt) fornecimento pulmonar de inibidores de fosfodiesterase do tipo 5
TW200505423A (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
WO2005034998A3 (en) Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
MX2007002311A (es) Antagonistas del receptor de endotelina a(eta) en combinacion con inhibidores de fosfodiesterasa 5 (pdes) y usos de los mismos.
UA83101C2 (en) 2,6-bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists
SI1957484T1 (sl) Antagonisti glukagonskega receptorja, priprava in terapevtske uporabe
MXPA06001815A (es) Preparado farmaceutico transdermico que contiene combinaciones de principios activos para el tratamiento de la enfermedad de parkinson.
WO2005092009A3 (en) Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders
TW200631956A (en) Azabenzoxazoles for the treatment of CNS disorders
TW200624125A (en) Compositions and methods for increasing HDL and HDL-2b levels
TW200738288A (en) Methods of transdermally administering an indole serotonin receptor agonist and transdermal compositions for use in the same
MY138394A (en) Combination of mglur2 antagonist and ache inhibitor
MX2009005798A (es) Recuperacion de apoplejia.
MXPA03009595A (es) Uso de antagonistas del canal de sodio neuronal para control de ectoparasitos de animales homeotermicos.
MX2007003158A (es) Forma cristalina 2 del clorhidrato de atrasentan.